Literature DB >> 16903922

Infectious tolerance and the long-term acceptance of transplanted tissue.

Herman Waldmann1, Elizabeth Adams, Paul Fairchild, Stephen Cobbold.   

Abstract

Short courses of antibody treatment aimed at blocking the coreceptors CD4 and CD8 and/or costimulatory molecules such as CD40L are able to bring about long-term acceptance and tolerance of allogeneic transplants. This tolerant state is operational, in that potential effector cells remain but are tightly regulated through the induction of antigen-specific CD4+ regulatory T cells (Tregs). CD4+ CD25+ FoxP3+ Tregs appear to play a prominent role, although other categories of Tregs have been documented. Transforming growth factor beta (TGFbeta) has been found to play a major role in the induction of the tolerant state with therapeutic antibodies as well as promoting the induction of FoxP3+ T cells from naïve populations. The observation that Tregs can be found in tolerated grafts has led to the idea that they may interact with the grafted tissue to establish a state of acquired privilege symmetrical with a similar privileged microenvironment around antigen-presenting cells in lymphoid tissues. Dampening of aggressive immune responses by Tregs allows antigen to persist and be presented in an innocuous way to promote tolerance in new cohorts of T cells throughout the life of the tolerated graft. Regulation may operate at many stages of an immune response, even as a censor at the terminal differentiation stages of effector function.

Entities:  

Mesh:

Year:  2006        PMID: 16903922     DOI: 10.1111/j.0105-2896.2006.00406.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  69 in total

1.  Distinct strategies are required to suppress antigen-specific responses to genetically modified keratinocytes and fibroblasts.

Authors:  Soosan Ghazizadeh; Li T Huang; Weibing Zhang
Journal:  Mol Ther       Date:  2011-10-11       Impact factor: 11.454

Review 2.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

Review 3.  Regulatory ripples.

Authors:  Yasmine Belkaid; Wanjun Chen
Journal:  Nat Immunol       Date:  2010-12       Impact factor: 25.606

4.  Immune responses against islet allografts during tapering of immunosuppression--a pilot study in 5 subjects.

Authors:  V A L Huurman; C R van der Torren; P Gillard; R Hilbrands; E P M W van der Meer-Prins; G Duinkerken; F K Gorus; F H J Claas; B Keymeulen; D L Roelen; D G Pipeleers; B O Roep
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

Review 5.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

Review 6.  Special regulatory T-cell review: A rose by any other name: from suppressor T cells to Tregs, approbation to unbridled enthusiasm.

Authors:  Ronald N Germain
Journal:  Immunology       Date:  2008-01       Impact factor: 7.397

7.  Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity.

Authors:  Noriko Komatsu; Maria Encarnita Mariotti-Ferrandiz; Ying Wang; Bernard Malissen; Herman Waldmann; Shohei Hori
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

8.  Adoptive T Regulatory Cell Therapy for Tolerance Induction.

Authors:  Cecilia Cabello-Kindelan; Shane Mackey; Allison L Bayer
Journal:  Curr Transplant Rep       Date:  2015-06-01

9.  Regulation and privilege in transplantation tolerance.

Authors:  Herman Waldmann; Elizabeth Adams; Paul Fairchild; Stephen Cobbold
Journal:  J Clin Immunol       Date:  2008-09-06       Impact factor: 8.317

10.  In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance.

Authors:  Andrea Annoni; Brian D Brown; Alessio Cantore; Lucia Sergi Sergi; Luigi Naldini; Maria-Grazia Roncarolo
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.